Eloxx Pharmaceuticals stock falls 1.49 percent as trial focus grows

Published on 09/22/2026 at 18:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Eloxx Pharmaceuticals stock closed at USD 17.19 on September 21, 2026, down 1.49 percent. Its Phase 2b study began dosing in September.

ELOX, US2901351052, Illustration mit AI erstellt.

Eloxx Pharmaceuticals (US2901351052) closed at USD 17.19 on Nasdaq on September 21, 2026, down 1.49 percent from the prior close. The company is now valued at USD 69.45 million, while the 52-week range runs from USD 8.20 to USD 23.40.

Phase 2b dosing sets the focus

According to MarketBeat on September 21, 2026, Eloxx Pharmaceuticals had announced first patient dosing in the Phase 2b EXACT study of exaluren for nonsense mutation Alport syndrome on September 11, 2026. The study milestone gives the stock a specific clinical reference point after the shares closed USD 6.21 below the 52-week high.

The company calendar shown by MarketBeat lists the last earnings date as August 11, 2026. That date and the September 11 dosing milestone frame the latest disclosed operating timeline for the company.

Small-cap biotech remains volatile

MarketBeat reported volume of 22,352 shares for September 21, 2026, compared with average volume of 38,227 shares. Trading therefore ran 15,875 shares below the stated average, while the closing price remained USD 8.99 above the 52-week low.

The stock's valuation is also modest in absolute terms, with market capitalization of USD 69.45 million on September 21, 2026. The gap between the USD 8.20 low and USD 23.40 high represents a USD 15.20 trading corridor, underscoring how strongly clinical milestones can shape a small biotechnology name.

Eloxx Pharmaceuticals stock closes at USD 17.19

Eloxx Pharmaceuticals stock closed at USD 17.19 on Nasdaq on September 21, 2026, with a daily change of minus 1.49 percent. The price was below the 52-week high of USD 23.40 and above the 52-week low of USD 8.20.